Ori Biotech To Use $30M Series A On Cell, Gene Therapy Manufacturing Platform

The London and Woodcliff Lake, New Jersey-based company is developing a platform that closes, automates and standardizes manufacturing for cell and gene therapy developers so they can move their treatments from the pre-clinical process through to scale commercially.

The company has been working with external partners over the past four months doing testing. One partner is already getting good results from testing the platform on its treatment for solid tumors, Ori Biotech’s CEO Jason Foster said in an interview.

Click here to read more.

Previous post
Back to list
Next post